Hansa Biopharma AB (OSTO:HNSA) Research & Development : kr421.5 Mil (TTM As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Hansa Biopharma AB Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Hansa Biopharma AB's Research & Development for the three months ended in Mar. 2024 was kr103.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was kr421.5 Mil.

Hansa Biopharma AB Research & Development Historical Data

The historical data trend for Hansa Biopharma AB's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hansa Biopharma AB Research & Development Chart

Hansa Biopharma AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Research & Development

Get a 7-Day Free Trial

192.95

227.19

230.76

346.24

411.33

Hansa Biopharma AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Research & Development	Get a 7-Day Free Trial															92.79	114.74	95.55	108.25	102.97

Hansa Biopharma AB Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr421.5 Mil.

Hansa Biopharma AB (OSTO:HNSA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Hansa Biopharma AB Research & Development Related Terms

Thank you for viewing the detailed overview of Hansa Biopharma AB's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Hansa Biopharma AB (OSTO:HNSA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hansa Biopharma AB (OSTO:HNSA) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

HNSBF:USA 0RC7:UK 24H:Germany

Address

Scheelevagen 22, Lund, SWE, 223 63

Website

https://www.hansabiopharma.com

Hansa Biopharma AB is a biopharmaceutical company that develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer. The company's product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in sensitized patients and further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. It operates in Sweden, other European countries, and the U.S. The group generates the majority of its revenue from product sales.

Hansa Biopharma AB (OSTO:HNSA) Headlines

No Headlines